home / stock / lpcn / lpcn quote
Last: | $5.20 |
---|---|
Change Percent: | 1.93% |
Open: | $5.03 |
Close: | $5.20 |
High: | $5.3021 |
Low: | $4.85 |
Volume: | 48,922 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.2 | $5.03 | $5.2 | $5.3021 | $4.85 | 48,922 | 03-28-2024 |
$5.1288 | $4.95 | $5.1288 | $5.3 | $4.95 | 20,882 | 03-27-2024 |
$5.01 | $4.42 | $5.01 | $5.27 | $4.36 | 73,049 | 03-26-2024 |
$4.4 | $4.07 | $4.4 | $4.4124 | $3.8033 | 38,945 | 03-25-2024 |
$4.04 | $4.13 | $4.04 | $4.2084 | $3.88 | 17,660 | 03-22-2024 |
$4.11 | $4.15 | $4.11 | $4.36 | $4.1 | 15,459 | 03-21-2024 |
$4.23 | $4.23 | $4.23 | $4.285 | $4.06 | 7,029 | 03-20-2024 |
$4.26 | $4.43 | $4.26 | $4.5765 | $4.22 | 14,672 | 03-19-2024 |
$4.49 | $4.6035 | $4.49 | $4.745 | $4.39 | 11,961 | 03-18-2024 |
$4.6 | $4.72 | $4.6 | $4.72 | $4.14 | 44,291 | 03-15-2024 |
$4.69 | $4.9 | $4.69 | $5.26 | $4.43 | 88,101 | 03-14-2024 |
$4.79 | $3.96 | $4.79 | $4.87 | $3.9401 | 109,298 | 03-13-2024 |
$3.96 | $3.57 | $3.96 | $4.0899 | $3.31 | 63,552 | 03-12-2024 |
$3.61 | $3.65 | $3.61 | $3.69 | $3.47 | 12,400 | 03-11-2024 |
$3.61 | $3.6 | $3.61 | $3.77 | $3.6 | 4,141 | 03-08-2024 |
$3.63 | $3.8162 | $3.63 | $3.8162 | $3.2 | 33,904 | 03-07-2024 |
$3.58 | $3.67 | $3.58 | $3.8499 | $3.51 | 10,988 | 03-06-2024 |
$3.64 | $3.67 | $3.64 | $3.67 | $3.4754 | 11,307 | 03-05-2024 |
$3.65 | $3.85 | $3.65 | $3.9323 | $3.63 | 12,956 | 03-04-2024 |
$3.83 | $3.7701 | $3.83 | $4 | $3.7701 | 9,102 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY , March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPC...
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today...